Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

November 4, 2015

Study Completion Date

November 4, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

SPIL1033

5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.

DRUG

Placebo

5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.

Trial Locations (34)

625020

SPIL Site 18, Madurai

Unknown

SPIL Site 22, Hyderabad

SPIL Site 25, Hyderabad

SPIL Site 26, Hyderabad

SPIL Site 23, Visakhapatnam

SPIL Site 1, Ahmedabad

SPIL Site 2, Ahmedabad

SPIL Site 3, Ahmedabad

SPIL Site 5, Rajkot

SPIL Site 6, Surat

SPIL Site 7, Surat

SPIL Site 8, Surat

SPIL Site 9, Surat

SPIL Site 10, Vadodara

SPIL Site 19, Bangalore

SPIL Site 30, Bangalore

SPIL Site 31, Bangalore

SPIL Site 33, Bangalore

SPIL Site 29, Manipal

SPIL Site 35, Indore

SPIL Site 21, Nagpur

SPIL Site 24, Nagpur

SPIL Site 32, Nashik

SPIL Site 11, Pune

SPIL Site 12, Pune

SPIL Site 13, Bhubaneshwar

SPIL Site 14, Jaipur

SPIL Site 15, Jaipur

SPIL Site 16, Chennai

SPIL Site 17, Coimbatore

SPIL Site 20, Coimbatore

SPIL Site 34, Vellore

SPIL Site 27, Lucknow

SPIL Site 28, Lucknow

All Listed Sponsors
lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT01406717 - Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter